arrow
A

Atish D. Choudhury

Dana-Farber Cancer Institute
H指数:29
被引数:5,890

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

6 Antitumor Activity of 177Lu-PSMA-617 in PSMA-Positive Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Results from a Phase 2 Trial (LASER)

6 177Lu-PSMA-617在PSMA阳性转移性透明细胞肾细胞癌(ccRCC)中的抗肿瘤活性:来自一项2期试验(LASER)的结果

2026-09-020
OAAI
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer

多模态循环游离DNA分析预测去甲长春花碱在转移性去势抵抗性前列腺癌中的疗效反应

2026-04-280
OAAI
Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer

出版更正:在激素敏感性前列腺癌中,早期停用LHRH-A后,阿比特龙/泼尼松单药治疗对睾酮的抑制与恢复作用

2025-11-180
PRE
Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer

雄激素抑制与恢复:在激素敏感性前列腺癌中,LHRH-A早期停药后使用阿比特龙/泼尼松单药治疗的效果

2025-10-270
PRE
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

阿贝西利布联合阿比特龙在转移性去势抵抗性前列腺癌患者中的研究(CYCLONE 2):一项随机、双盲、安慰剂对照、Ⅲ期临床试验

2025-10-270
PRE
Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging

骨髓疾病对血液学毒性和[177Lu]Lu-PSMA-617治疗反应的影响:来自PSMA-PET/CT成像的见解

2025-09-050
PRE
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer

血浆表观基因组分析揭示了前列腺癌中治疗相关的鳞状细胞转化。

2025-07-090
OAAI
Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

177Lu-Vipivotide Tetraxetan治疗后转移性去势抵抗性前列腺癌的后续治疗方案结果:一家三级癌症中心的经验

2025-03-180
PRE
Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone
2024-11-200
PRE
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer

联合固定疗程系统性治疗和转移灶定向放疗治疗寡转移性激素敏感性前列腺癌

2024-11-010
PRE
Insulin resistance during androgen deprivation therapy in men with prostate cancer

前列腺癌男性雄激素剥夺治疗期间的胰岛素抵抗

CANCER
IF5.1
2024-06-162
PRE
NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
2024-04-050
PRE
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
CANCER
IF5.1
2024-01-014
PRE